04:44 PM EDT, 03/20/2024 (MT Newswires) -- Fusion Pharmaceuticals ( FUSN ) late Wednesday reported a Q4 net loss of $0.39 per diluted share, compared with a $0.55 loss a year earlier.

Analysts polled by Capital IQ expected a loss of $0.33.

The company did not report any revenue for the quarter ended Dec. 31 compared with $140,000 a year earlier.

Analysts expected $460,000. The company had cash, cash equivalents and investments of $247.3 million.

Fusion Tuesday agreed to be acquired by AstraZeneca ( AZN ) for $21 per share in cash, or about $2 billion on closing of the deal.

AstraZeneca ( AZN ) will also $3 per share in cash payable upon the achievement of a specified regulatory milestone.

The deal is expected to close during Q2.

Price: 21.1, Change: +0.01, Percent Change: +0.05